PWPeter Wahlqvist

Peter Wahlqvist

*This is an algorithmically generated author record based on publicly available information.

Peter Wahlqvist has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of extended-release quetiapine fumarate on hospitalization length and cost in schizophrenia and bipolar disorder patients: a retrospective, hospital-based, US-cohort analysis

    by Julie C Locklear, Peter Wahlqvist, Urban Gustafsson, Mattias Udd, Liberty Liberty Fajutrao, Hans Eriksson

    Aim: The aim was to evaluate the impact of quetiapine extended release (XR) on hospitalization length and cost in schizophrenia or bipolar disorder, versus quetiapine immediate release (IR), using Premier Perspective (TM) inpatient hospital database data. Methods: Inpatient discharges classified within diagnosis-related group 430 (psychoses), prescribed quetiapine XR or IR, were identified. Patients had International Classification of Disease-9 diagnosis of schizophrenia or bipolar disorder. The impact of the XR formulation on hospitalization length and costs was assessed using generalized linear model analyses. Results: A total of 30,429 discharges between 1 January 2008 and 30 June 2009 were analyzed. Patients who received quetiapine XR had significantly reduced hospitalization length (10.73% estimated reduction; p = 0.001) and cost (9.52% estimated reduction; p < 0.001), versus IR. This corresponds to a 1.0-day reduction in hospitalization (10.73% of 9.2 days) and US$532 reduction in hospitalization cost (9.52% of US$5588) per patient, based on least squares mean estimations. Evaluation of patient subpopulations suggested the reduction in length of hospitalization for quetiapine XR versus IR was driven mainly by patients with bipolar disorder, whereas cost reduction was driven mainly by patients with schizophrenia. Conclusion: Inpatient use of quetiapine XR in schizophrenia or bipolar disorder is associated with reduced hospitalization length and cost, possibly due to the faster titration schedule versus quetiapine IR.

  • Open Access

    Cost and burden of gastroesophageal reflux disease among patients with persistent symptoms despite proton pump inhibitor therapy: an observational study in France

    by Stanislas Bruley Des Varannes, Helena Granstedt Löfman, Maria Karlsson, Peter Wahlqvist, Magnus Ruth, Mary Lou Furstnau, Nicolas Despiégel, Nils-Olov Stålhammar

    Background: Gastrointestinal reflux disease (GERD) is a common disorder that negatively impacts health-related quality of life (HRQL) and work productivity. Many patients have only a partial response to proton pump inhibitor (PPI) therapy and continue to experience GERD symptoms despite optimized treatment. This observational study aimed to provide information on symptoms, HRQL, resource usage, costs and treatment pathways associated with partial response to PPI therapy in French patients with GERD. Methods: Patients with partial response to PPI therapy, defined as persistent GERD symptoms ≥3 days/week despite optimized treatment with a PPI, were recruited for this 12-month observational study. GERD symptoms, HRQL, work productivity and resource use were assessed by patient surveys. Costs were calculated based on lost work productivity and resource use. Results: The patient population (n=262; mean age, 54 years; 40% men) carried a significant symptom burden, with 98% of patients having moderate-to-severe GERD symptoms and 65% of patients experiencing daily symptoms at baseline. HRQL and work productivity were significantly impaired, with a greater degree of impairment in patients with higher symptom burden. The mean total cost per patient over the 12-month follow-up period was €5237, of which €4674 (89%) was due to lost work productivity. Conclusions: Partial response to PPI therapy for GERD is associated with a high symptom burden, significant impairment of HRQL and work productivity, and substantial GERD-related costs.


  • 225 Intravenous Esomeprazole for Prevention of Peptic Ulcer Re-Bleeding in a Predominantly Caucasian Population: Results On Clinical Benefits and Hospital Resource Use

    by Alan N. Barkun, Joseph J. Sung, Ernst J. Kuipers, Joachim Mössner, Dennis M. Jensen, Robert Stuart, James Y. Lau, Henrik Ahlbom, Jan Kilhamn, Peter Wahlqvist, et al.

  • Open Access

    Relationship between symptom load of gastro‐oesophageal reflux disease and health‐related quality of life, work productivity, resource utilization and concomitant diseases: survey of a US cohort

    by P. Wahlqvist, M. Karlsson, D. Johnson, J. Carlsson, S. C. Bolge, M.‐A. Wallander

    Summary: Background  Analysis of the burden of gastro‐oesophageal reflux disease (GERD) in relation to the severity and frequency of symptoms is essential to identify individuals and groups in whom targeted management is justified.Aim  To describe the relationship between symptoms of GERD and self‐reported health‐related quality of life (HRQL), work productivity, healthcare utilization and concomitant diseases.Methods  US respondents to the Internet‐based 2004 National Health and Wellness Survey who had self‐reported GERD (n = 10 028, mean age: 52 years, 58% female) were age‐ and gender‐matched to a control group without GERD (n = 10 028). Respondents with GERD were classified according to symptom severity and frequency. HRQL and productivity were assessed using the Short‐Form 8 survey (SF‐8) and Work Productivity and Activity Impairment questionnaire, respectively.Results  Symptom frequency increased with increasing symptom severity. Compared with controls, respondents with GERD had more concomitant diseases [mean difference (MD): 1.6], lower SF‐8 physical and mental health scores (MD: 4.1 units and 3.1 units, respectively), increased absenteeism (MD: 0.9 h/week), reduced percent productivity at work (MD: 7.5%) and increased healthcare utilization. All tested variables deteriorated with increasing symptom severity and/or frequency.Conclusions  Increasing severity and frequency of GERD symptoms is associated with more concomitant diseases, lower HRQL, lower work productivity and increased healthcare utilization, suggesting that patients with moderate or severe GERD should receive targeted management with the most effective treatment strategies.


  • The Work Productivity and Activity Impairment Questionnaire for Patients with Gastroesophageal Reflux Disease (WPAI-GERD)

    by Peter Wahlqvist, Gordon H. Guyatt, David Armstrong, Alessio Degl’innocenti, Diane Heels-Ansdell, Samer El-Dika, Ingela Wiklund, Carlo A. Fallone, Lisa Tanser, Sander Veldhuyzen van Zanten, et al.

    Background A validated productivity questionnaire, the Work Productivity and Activity Impairment questionnaire for Gastroesophageal Reflux Disease (WPAIGERD), exists for Swedish patients with GERD.


  • Systematic review: the impact of gastro‐oesophageal reflux disease on work productivity

    by P. Wahlqvist, M. C. Reilly, A. Barkun

    Summary: Background: Gastro‐oesophageal reflux disease has wide‐ranging effects on patients’ lives.Aim: To review systematically the effects of gastro‐oesophageal reflux disease on work productivity.Methods: Studies of gastro‐oesophageal reflux disease and work productivity were identified in a systematic literature search and their results were valued in US dollars using the human capital method. Work productivity loss was defined as absence from work (absenteeism) plus reduced effectiveness while working (presenteeism).Results: Eight eligible studies were included. Reported work productivity loss among individuals with gastro‐oesophageal reflux disease ranged from 6% to 42% and was primarily because of presenteeism (6–40%) rather than absenteeism (<1% to 7%). Reported losses were greatest in patients experiencing sleep disturbance because of gastro‐oesophageal reflux disease, and lowest in individuals from the general population taking appropriate prescription medication. Work productivity impairment correlated with symptom severity and responded to acid‐suppressive therapy. Assuming a 40‐h working week and average wages in the US, the weekly mean productivity loss per employee with gastro‐oesophageal reflux disease can be estimated between 2.4 ($62) and 16.6 h ($430), depending on the population studied.Conclusions: Gastro‐oesophageal reflux disease has a substantial impact on employee productivity, primarily by impairing productivity while working. Further studies are needed to confirm that this impact can be decreased by acid‐suppressive therapy.


  • Open Access

    The impact of illness in patients with moderate to severe gastro-esophageal reflux disease

    by Samer El-Dika, Gordon H Guyatt, David Armstrong, Alessio Degl'Innocenti, Ingela Wiklund, Carlo A Fallone, Lisa Tanser, Sander Veldhuyzen van Zanten, Diane Heels-Ansdell, Peter Wahlqvist, et al.

    Background Gastro-esophageal reflux disease (GERD) is a common disease. It impairs health related quality of life (HRQL). However, the impact on utility scores and work productivity in patients with moderate to severe GERD is not well known. Methods We analyzed data from 217 patients with moderate to severe GERD (mean age 50, SD 13.7) across 17 Canadian centers. Patients completed three utility instruments – the standard gamble (SG), the feeling thermometer (FT), and the Health Utilities Index 3 (HUI 3) – and several HRQL instruments, including Quality of Life in Reflux and Dyspepsia (QOLRAD) and the Medical Outcomes Short Form-36 (SF-36). All patients received a proton pump inhibitor, esomeprazole 40 mg daily, for four to six weeks. Results The mean scores on a scale from 0 (dead) to 1 (full health) obtained for the FT, SG, and HUI 3 were 0.67 (95% CI, 0.64 to 0.70), 0.76 (95% CI, 0.75 to 0.80), and 0.80 (95% CI, 0.77 to 0.82) respectively. The mean scores on the SF-36 were lower than the previously reported Canadian and US general population mean scores and work productivity was impaired. Conclusion GERD has significant impact on utility scores, HRQL, and work productivity in patients with moderate to severe disease. Furthermore, the FT and HUI 3 provide more valid measurements of HRQL in GERD than the SG. After treatment with esomeprazole, patients showed improved HRQL.


  • Cost Effectiveness of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease Without Oesophagitis

    by Peter Wahlqvist, Ola Junghard, Andy Higgins, Jonathan Green

    To evaluate the cost effectiveness of on-demand treatment with esomeprazole 20mg compared with two alternative omeprazole treatment strategies for the long-term management of patients with gastro-oesophageal reflux disease (GORD) without oesophagitis. A simple Markov model was designed to compare the cost effectiveness of on-demand esomeprazole 20mg therapy for 6 months with a strategy consisting of intermittent 4-week acute treatment courses of omeprazole 20mg once daily or a strategy consisting of continuous omeprazole treatment (20mg once daily) following acute treatment of first relapse while on no drug treatment (a commonly used conventional care strategy). Relapse probabilities were based on pooled results from two 6-month placebo-controlled clinical studies of on-demand esomeprazole 20mg treatment in patients with GORD without oesophagitis and on results from a GORD study with a 6-month untreated follow-up. The expected number of relapses per patient was used as the effectiveness measure. SETTING AND PERSPECTIVE: Patient management assumptions were based on a UK physician survey. The cost-effectiveness analysis considered UK direct medical costs from the perspective of the National Health Service. The pooled analysis showed that after 6 months treatment, 90% of patients could control symptoms effectively with on-demand esomeprazole 20mg. The expected number of relapses per patient was estimated at 0.10 for on-demand esomeprazole, 0.57 to 1.12 for intermittent omeprazole and 0.47 to 0.75 for conventional omeprazole treatment. The esomeprazole strategy incurred considerably lower direct medical costs (16 to 61%) than either omeprazole strategy. On-demand treatment with esomeprazole 20mg is cost effective compared with two alternative omeprazole treatment strategies in patients with GORD without oesophagitis.